Log in or Sign up for Free to view tailored content for your specialty!
Anemia Management News
Akebia readies launch of anemia drug Vafseo; planning talks with FDA on pre-dialysis use
As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.
Hydralazine-induced autoimmune conditions may include drug-induced lupus, vasculitis
LONG BEACH, Calif. — Hydralazine-induced autoimmune conditions may have a varied presentation, including drug-induced lupus or vasculitis, according to a speaker, here.
Study finds clinicians do not consistently use algorithms when dosing Mircera
LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows.
Log in or Sign up for Free to view tailored content for your specialty!
Investigational drug that reduces hepcidin offers promise for treating anemia
LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.
Akebia receives FDA approval for anemia drug Vafseo
Akebia Therapeutics Inc. has received FDA approval for its oral anemia drug Vafseo for treating anemia in adults with end-stage kidney disease on dialysis for at least 3 months.
Revisit news and research in anemia
Healio has compiled a list of its most-read anemia care news in 2023.
Study: More staff, communication needed after ‘graduating’ patients after transplantation
PHILADELPHIA — Many kidney transplant patients successfully advance from transplant centers back to their local nephrologists, but providers find there is room for improvement in the transition, according to data presented at ASN Kidney Week.
Wish reviews progress in anemia management and potential for a new drug class
Healio | Nephrology News & Issues interviewed Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, about the role of anemia management in kidney care. Wish is also chair of the Editorial Advisory Board for Healio | Nephrology News & Issues.
New anemia drugs could change the steady state of kidney care
During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to treat anemia in patients with end-stage kidney disease. That has now changed.
Survey shows limited uptake with new anemia drugs
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors, according to a poster presentation at ASN Kidney Week.
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read
-
Headline News
‘The mind is medicine’: How virtual reality can cool bothersome hot flashes
September 18, 20244 min read -
Headline News
CDC: Close contact of Missouri bird flu case had symptoms but was not tested
September 17, 20242 min read -
Headline News
Metformin use may lower risk for long COVID in adults with type 2 diabetes
September 18, 20243 min read